|
Active substance |
BAF312 |
|
Holder |
Novartis Pharma NV |
|
Status |
Closed |
|
Indication |
Treatment for adult patients with Secondary Progressive Multiple Sclerosis (SPMS). |
|
Public documents |
|
| Approbation amendment | |
|
Last update |
05/11/2021 |
Siponimod
Last updated on 13/09/2024